The results of a long-term open-label extension trial of plant-derived, highly purified cannabidiol show the treatment is effective and safe for patients with Lennox-Gastaut syndrome, an often treatment-resistant seizure disorder. The treatment had a similar safety profile as in the original randomized controlled trials and resulted in a drop in seizure frequency for up to 156 weeks.

Read more at Pediatrics Nationwide: Long-Term Follow-Up Study Shows Cannabidiol is Safe and Effective for Lennox-Gastaut Syndrome.